Navigation Links
Results From Investigator-Sponsored Trials Presented at SSIEM Conference
Date:9/1/2010

Response to treatment can only be determined by a therapeutic trial of Kuvan.

Kuvan has not been studied in patients with liver or renal impairment. Patients who have these conditions should be carefully monitored when receiving Kuvan. Caution should be used with the administration of Kuvan to patients who are receiving levodopa and drugs that affect nitric oxide–mediated vasorelaxation or folate metabolism.

The most serious adverse reactions reported during Kuvan administration (regardless of relationship to treatment) were gastritis, spinal cord injury, streptococcal infection, testicular carcinoma, and urinary tract infection. Mild to moderate neutropenia was also noted. The most common adverse reactions were headache, diarrhea, abdominal pain, upper respiratory tract infection, pharyngolaryngeal pain, vomiting, and nausea.

About PKUPKU, a genetic disorder affecting approximately 50,000 diagnosed patients in the developed world, is caused by a deficiency of the enzyme phenylalanine hydroxylase (PAH). PAH is required for the metabolism of phenylalanine, an essential amino acid found in most protein-containing foods. If the active enzyme is not present in sufficient quantities, Phe accumulates to abnormally high levels in the blood and becomes toxic to the brain, resulting in a variety of complications including severe mental retardation and brain damage, mental illness, seizures, tremors, and limited cognitive ability. As a result of newborn screening efforts implemented in the 1960s and early 1970s, virtually all PKU patients under the age of 40 in developed countries have been diagnosed at birth. To learn more about PKU, please visit www.PKU.com. Information on this website is not incorporated by reference into this press release.

About BioMarinBioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio com
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Proprietary Zinc/Phytase Formulation Improved Botulinum Toxin A Results
2. Accuray Announces Results for Fourth Quarter and Fiscal Year 2010
3. CORDIS Announces Results of Ten-Year CYPHER(R) Sirolimus-Eluting Coronary Stent Follow-Up
4. Unilife Corporation Announces Preliminary Financial Results for Fourth Quarter and Fiscal Year 2010
5. Cyberonics Reports Strong Fiscal 2011 First Quarter Results
6. Preliminary Research Results Suggest up to 70% Reduction in Dose for Positron Emission Mammography Imaging
7. Topline Results From Phase 3 Trial of Sunitinib With Erlotinib in Advanced Non-Small Cell Lung Cancer (NSCLC)
8. MedClean Technologies Announces Second Quarter Results
9. Kensey Nash Reports Fourth Quarter and Full Fiscal Year 2010 Financial Results
10. Huifeng Bio-Pharmaceutical Reported Second Quarter 2010 Financial Results and Reaffirms its 2010 Guidance
11. China Yongxin Pharmaceuticals Reports Second Quarter 2010 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... NxStage Medical, Inc. (NASDAQ: NXTM ... announced today that the U.S. Food and Drug ... perform hemodialysis overnight while the patient is at ... System One is the first and only hemodialysis ... Home nocturnal hemodialysis is an ...
(Date:12/22/2014)... 22, 2014 Research and Markets ... the "Investment Analysis of the US Medical ... http://photos.prnewswire.com/prnh/20130307/600769 ... medical device sector identifies the key trends and ... investments, and mergers and acquisitions. The ...
(Date:12/22/2014)... Dec. 22, 2014 /PRNewswire/ -- RXi Pharmaceuticals Corporation (NASDAQ: ... on discovering, developing and commercializing innovative therapies addressing ... issued the following open letter to shareholders from ... Med. Sc. Dear RXi Shareholders, ... of inaccurate statements posted on certain social media ...
Breaking Medicine Technology:NxStage Receives FDA Clearance for Home Nocturnal Hemodialysis 2NxStage Receives FDA Clearance for Home Nocturnal Hemodialysis 3Investment Analysis of the US Medical Device Sector 2RXi Pharmaceuticals Issues Open Letter to Shareholders 2RXi Pharmaceuticals Issues Open Letter to Shareholders 3RXi Pharmaceuticals Issues Open Letter to Shareholders 4RXi Pharmaceuticals Issues Open Letter to Shareholders 5RXi Pharmaceuticals Issues Open Letter to Shareholders 6
... Raylene Riha and her husband, Michael, filed suit today ... seeking compensation for injuries caused by failures of Raylene,s ... been recalled.  John David Hart of the Law Offices ... the attorney representing Raylene and Michael Riha in the ...
... Watson Pharmaceuticals, Inc. (NYSE: WPI ) ...  and Watson Laboratories, Inc. -- Florida, (collectively "Watson") ... U.S. Food and Drug Administration (FDA) seeking approval ... 10,15, 20, 30, 40, 60 and 80 mg ...
Cached Medicine Technology:Law Offices of John David Hart: DePuy Recalled Hip Device Lawsuit Filed by Houston Woman 2Watson Confirms OxyContin® Patent Challenge 2Watson Confirms OxyContin® Patent Challenge 3
(Date:12/26/2014)... Orlando, FL (PRWEB) December 26, 2014 ... visitor health insurance in the USA, announced today a ... to assist members in choosing the right plan for ... take the complexity out of the selection process when ... premiums by age group with only a few clicks. ...
(Date:12/25/2014)... The microscopy market is estimated to ... $5,756.0 million by 2019. Optical microscopy is the ... microscopes product segment is expected to show the ... focus on nanotechnology, technological advancements, and increasing federal ... , Get Full Copy of Report @ ...
(Date:12/25/2014)... 26, 2014 The report “TS-1 (Colorectal ... on the current treatment landscape, unmet needs, current pipeline ... is an anti-cancer drug which is typically used for ... also used for treating gastric cancer and pancreatic cancer. ... The drug was first approved in 1999 in Japan ...
(Date:12/25/2014)... Dylan Queen, a famous online company supplying women’s special ... prom dresses, most of which are priced under $200. ... the promotion is valid until Jan. 22, 2015; the ... market. , The prom dresses in this new collection ... strapless, empire strapless chiffon, one shoulder, floor-length, V-neck beading, ...
(Date:12/25/2014)... December 25, 2014 Helen Harris’ RP ... Woodland Hills, California after an 8 year battle with ... Christmas Eve evening in her home in Woodland Hills ... breast cancer. , As the founder ... years, she pioneered and championed many of today's greatest ...
Breaking Medicine News(10 mins):Health News:India Network Health Insurance Announces new Comprehensive Pre-existing Condition Coverage policy for Visitors to the United States 2Health News:India Network Health Insurance Announces new Comprehensive Pre-existing Condition Coverage policy for Visitors to the United States 3Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 2Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 3Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 4Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Dylan Queen: Cheap Prom Dresses for the UK Market 2Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 2Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 3Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 4
... technique could speed the diagnosis, French researchers say ... radiologists report they,ve simplified a method of scanning ... making it easier to diagnose the mind-robbing condition. ... routinely using the approach, but early tests are ...
... DIEGO, June 24 Behavioral Risk Management is ... the strong message from,a survey conducted by the ... and effectiveness in Behavioral Risk,Management., Additionally, survey ... beyond an emerging focus area to one that ...
... Abusing Prescription Medications Get ... or Friend, NEW YORK, June 24 A house ... secure, yet it is here that teens are,prone to get ... drug misuse and abuse, the Partnership for a Drug-Free,America(R) and ...
... announced the launch of the 3M™ Filtron™ 1900 tie-on ... seeking a premium surgical mask. The new 3M ... a rayon outerlayer to deliver increased breathability and comfort, ... a popular "duckbill" design, the 3M Filtron 1900 surgical ...
... Year Revenue Guidance to a range of $395 Million to $405 ... ... Revenue of $101.9 million, up 57.4% over first quarter 2007 - Gross ... income of $9.6 million, up 135.4% over first quarter 2007, WARSAW, Ind., June ...
... Way to Fight Common Illnesses, HOLLYWOOD, Calif., June ... site, http://www.help2getbetter.com, and the sale,of online sick ... fight common illnesses. What makes these sick packs unique ... but come packaged,together conveniently in one- or two-dose portion ...
Cached Medicine News:Health News:Brain Scans Detect Alzheimer's Disease Quickly 2Health News:Brain Scans Detect Alzheimer's Disease Quickly 3Health News:Behavioral Risk in the Workplace: Behavioral Risk Management Continues to be an Important Best Practice Area for Employers 2Health News:Abbott and Partnership for a Drug-Free America Launch 'Not In My House' to Help Parents Secure Their Homes from Teen Prescription Drug Misuse and Abuse 2Health News:Abbott and Partnership for a Drug-Free America Launch 'Not In My House' to Help Parents Secure Their Homes from Teen Prescription Drug Misuse and Abuse 3Health News:3M Health Care launches new high-performance surgical mask 2Health News:Symmetry Medical Reports Record First Quarter 2008 Revenue of $101.9 Million 2Health News:Symmetry Medical Reports Record First Quarter 2008 Revenue of $101.9 Million 3Health News:Symmetry Medical Reports Record First Quarter 2008 Revenue of $101.9 Million 4Health News:Symmetry Medical Reports Record First Quarter 2008 Revenue of $101.9 Million 5Health News:Symmetry Medical Reports Record First Quarter 2008 Revenue of $101.9 Million 6Health News:Symmetry Medical Reports Record First Quarter 2008 Revenue of $101.9 Million 7Health News:Symmetry Medical Reports Record First Quarter 2008 Revenue of $101.9 Million 8Health News:Launch of help2getbetter.com Provides Convenience and Portability to Household Medicines 2
Immunoturbidimetric assay for the quantitative in vitro determination of Lipoprotein (a) in human serum or plasma...
For the quantitative in vitro determination of Digitoxin in human serum....
For the quantitative in vitro determination of Phenytoin in human serum....
For the quantitative in vitro determination of Phenobarbital in human serum....
Medicine Products: